RD Lewis Holdings Inc. purchased a new position in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 23,968 shares of the biopharmaceutical company's stock, valued at approximately $617,000.
Other hedge funds have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the fourth quarter worth about $28,000. Noble Wealth Management PBC bought a new position in shares of Pfizer in the fourth quarter worth about $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer during the 4th quarter worth about $32,000. 68.36% of the stock is currently owned by institutional investors.
Pfizer Stock Performance
PFE traded up $0.26 during trading on Tuesday, reaching $26.31. 32,949,032 shares of the company's stock were exchanged, compared to its average volume of 35,799,303. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $149.09 billion, a P/E ratio of 18.66, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company's fifty day simple moving average is $26.21 and its 200-day simple moving average is $27.09.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the firm posted $0.10 EPS. Pfizer's revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Analysts Set New Price Targets
PFE has been the topic of several recent research reports. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Bank of America reiterated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. StockNews.com cut shares of Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.
Check Out Our Latest Stock Report on Pfizer
Insiders Place Their Bets
In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is currently owned by insiders.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
